Bristol-Myers Squibb: Renal Insufficiency trials

The registry lists 15 Renal Insufficiency studies with Bristol-Myers Squibb as lead sponsor. 0 are open to participants now and 3 have results posted.

Phase 1 12Phase 2 2Phase 3 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Phase 2 Study of Intravenous or Subcutaneous Dosing of Sotatercept (ACE-011) in Patients With End-Stage Kidney Disease on HemodialysisCompletedNCT01999582Phase 2Results posted
• Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal FunctionCompletedNCT00652626Phase 1Results posted
• Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)CompletedNCT00256750Phase 3Results posted
• A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent HemodialysisCompletedNCT06723535Phase 1
• A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal ImpairmentCompletedNCT06318676Phase 1
• Study to Evaluate Safety and Tolerability of Iberdomide (CC-220) in Participants With Kidney Impairment Compared to Participants With Normal Kidney FunctionCompletedNCT04933747Phase 1
• A Study to Evaluate the Pharmacokinetics (Drug Levels and Metabolism), Safety, and Tolerability of BMS-986259 in Participants With Various Levels of Kidney FunctionCompletedNCT04237831Phase 1
• A Study to Assess the Safety of Experimental Medication BMS986165 in Participants With Normal Kidney Function and Participants With Mild to End-Stage Kidney Disease.CompletedNCT03890770Phase 1
• A Study of Experimental Medication BMS-986231 in Patients With Different Levels of Kidney FunctionCompletedNCT03332186Phase 1
• A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal ImpairmentCompletedNCT03097016Phase 1
• A Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunction on Chronic Stable Hemodialysis TreatmentCompletedNCT02902679Phase 1
• Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal InsufficiencyCompletedNCT02045017Phase 2
• Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal ImpairmentCompletedNCT01763190Phase 1
• Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal DysfunctionCompletedNCT01708889Phase 1
• Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)CompletedNCT01575925Phase 1